We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » EMA: Less Data Required for Expanding Orphan Drug Indications
EMA: Less Data Required for Expanding Orphan Drug Indications
The European Medicines Agency published new guidance on whether less comprehensive data can be used to support a new indication for a previously approved orphan drug product.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor